For the quarter ending 2025-09-30, BCRX had -$4,086K decrease in cash & cash equivalents over the period. $53,743K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|
| Loss on extinguishment of debt | -6,911 | - | 0 |
| Net income (loss) | 18,016 | - | -88,881 |
| Depreciation and amortization | 995 | - | 1,246 |
| Inventory obsolescence | 1,056 | - | 1,350 |
| Stock-based compensation expense | 61,273 | - | 65,413 |
| Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs | - | - | 67,607 |
| Amortization of discount on investments, net | -3,240 | - | -11,473 |
| Loss on impairment | - | - | 0 |
| Increase in receivables | 21,312 | - | 22,698 |
| Increase in inventory | 1,124 | - | 4,164 |
| (increase) decrease in prepaid expenses and other assets | 5,890 | - | -1,959 |
| Increase (decrease) in accounts payable and accrued expenses | 22,441 | - | -62,379 |
| Deferred revenue | - | - | 0 |
| Net cash provided by (used in) operating activities | 55,409 | - | -52,020 |
| Acquisitions of property and equipment | 1,666 | - | 1,124 |
| Purchases of investments | 136,737 | - | 266,763 |
| Sales and maturities of investments | 207,647 | - | 320,480 |
| Net cash provided by investing activities | 69,794 | - | 52,593 |
| Net proceeds from common stock issued under stock-based compensation plans | 8,458 | - | 3,444 |
| Common stock issued to directors in lieu of cash retainer | 36 | - | 34 |
| Withholding taxes paid on stock-based awards | 2,845 | - | 7,535 |
| Net proceeds from secured term loans | - | - | 0 |
| Repayment of athyrium secured term loans principal | - | - | 0 |
| Prepayment and repayment fees on athyrium secured term loans | - | - | 0 |
| Payment of debt issuance costs on pharmakon tranche a term loan | - | - | 0 |
| Principal payments on finance lease liabilities | 1,565 | - | 1,704 |
| Net cash used in financing activities | -131,971 | - | -5,761 |
| Less net increase in cash and cash equivalents classified within current assets held for sale | - | 15,058 | - |
| Effect of exchange rates on cash, cash equivalents and restricted cash | - | - | -936 |
| Cash Cash Equivalent Restricted Cash And Restricted Cash Equivalent Period Increase Decrease Including Exchange Rate Effect Continuing Operations Excluding Assets Held For Sale | - | -16,398 | - |
| Decrease in cash, cash equivalents and restricted cash | - | - | -6,124 |
| Net decrease in cash, and cash equivalents, and restricted cash | -4,086 | -1,340 | - |
BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX)